Skip to main content
. Author manuscript; available in PMC: 2018 Dec 28.
Published in final edited form as: Cancer Res. 2014 Sep 9;74(21):5989–5998. doi: 10.1158/0008-5472.CAN-13-2042

Figure 6. DNA vaccination with pcDNA3.1-HMGN1-gp100 plasmid protected mice from B16F1 inoculation.

Figure 6

C57BL/6 mice (7-week old, female, 5 mice/group) were DNA vaccinated with indicated plasmids via gene gun twice a week for 3 consecutive weeks with the exception of group 6, in which mice received only two (the first and the last) vaccinations. Six days after the last vaccination, mice were subcutaneously implanted with B16F1 melanoma (2×104/0.2 ml/mouse). Tumor growth was monitored twice a week for up to 4 weeks, starting on day 6 after B16 implantation. A, Schematic illustration of the time line of various treatments. B, Tumor growth curve. Shown are the results of one experiment representative of two. *p < 0.05 by Repeated Measures ANOVA in comparison with pcDNA3.1 control group.